COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB VERSUS ADALIMUMAB, INFLIXIMAB AND VEDOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH MODERATELY TO SEVERE ACTIVE CROHN'S DISEASE FOR TURKEY


Creative Commons License

Arhan M., Tezel H. A., TÖRÜNER M., Bilaloglu B., Koral S., Ozer E.

VALUE IN HEALTH, cilt.21, 2018 (SCI-Expanded) identifier